Insulin Regulation of Lipolysis and Lipolysis Proteins
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
These studies will define the abnormalities in the adipocyte proteins that are involved in
the failure of insulin to suppress lipolysis normally in humans with upper body obesity and
will help discover the mechanism by which pioglitazone, a medication used to treat type 2
diabetes and improve insulin resistance, improves insulin-regulation of adipocyte fatty acid
metabolism.
Phase:
Early Phase 1
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)